Histone deacetylase inhibitors: a novel class of therapeutic agents in diabetic nephropathy.
作者： H.B. Lee , H. Noh , J.Y. Seo , M.R. Yu , H. Ha
关键词:
摘要: Histone deacetylase (HDAC) inhibitors are currently being tested as anticancer agents in clinical trials. Chromatin remodeling, such through histone acetylation, is a fundamental phenomenon eukaryotic cell biology, bearing implications to numerous physiological and pathological phenomena. Here, we discuss recent data from our own laboratory those of others demonstrating antifibrotic renoprotective effect HDAC diabetic kidneys, the possible mechanisms including role reactive oxygen species. may prove be novel class multitarget treatment nephropathy.
kidney-international.org
nature.com
sci-hub.se 参考文章(47)
M. Wartmann, R.J. Davis, The native structure of the activated Raf protein kinase is a membrane-bound multi-subunit complex. Journal of Biological Chemistry. ,vol. 269, pp. 6695- 6701 ,(1994) , 10.1016/S0021-9258(17)37431-8
Jorge A. Almenara, Roberto R. Rosato, Steven Grant, The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Research. ,vol. 63, pp. 3637- 3645 ,(2003)
D. Barit, Mark E. Cooper, S. Giunti, Diabetic nephropathy: from mechanisms to rational therapies. Minerva Medica. ,vol. 97, pp. 241- 262 ,(2006)
Junwei Yang, Youhua Liu, Dissection of Key Events in Tubular Epithelial to Myofibroblast Transition and Its Implications in Renal Interstitial Fibrosis American Journal of Pathology. ,vol. 159, pp. 1465- 1475 ,(2001) , 10.1016/S0002-9440(10)62533-3
Judd C Rice, C.David Allis, Histone methylation versus histone acetylation: new insights into epigenetic regulation. Current Opinion in Cell Biology. ,vol. 13, pp. 263- 273 ,(2001) , 10.1016/S0955-0674(00)00208-8
Daniel Riester, Christian Hildmann, Andreas Schwienhorst, Histone deacetylase inhibitors--turning epigenic mechanisms of gene regulation into tools of therapeutic intervention in malignant and other diseases. Applied Microbiology and Biotechnology. ,vol. 75, pp. 499- 514 ,(2007) , 10.1007/S00253-007-0912-1
Frédéric Blanchard, Céline Chipoy, Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases? Drug Discovery Today. ,vol. 10, pp. 197- 204 ,(2005) , 10.1016/S1359-6446(04)03309-4
A. A. Ruefli, M. J. Ausserlechner, D. Bernhard, V. R. Sutton, K. M. Tainton, R. Kofler, M. J. Smyth, R. W. Johnstone, The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proceedings of the National Academy of Sciences of the United States of America. ,vol. 98, pp. 10833- 10838 ,(2001) , 10.1073/PNAS.191208598
Nilanjan Sengupta, Xiaohong Zhang, Edward Seto, Michele A. Glozak, Acetylation and deacetylation of non-histone proteins Gene. ,vol. 363, pp. 15- 23 ,(2005) , 10.1016/J.GENE.2005.09.010
Song Wang, Qing Chen, Theodore C. Simon, Frank Strebeck, Lala Chaudhary, Jeremiah Morrissey, Helen Liapis, Saulo Klahr, Keith A. Hruska, Bone morphogenic protein-7 (BMP-7), a novel therapy for diabetic nephropathy11Professor Robert Chevalier served as a guest editor for this paper. Kidney International. ,vol. 63, pp. 2037- 2049 ,(2003) , 10.1046/J.1523-1755.2003.00035.X